Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
|
News Articles on Mylan Inc.Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines AssociationPITTSBURGH, Nov. 18 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Didier Barret, president of Mylan Europe, Middle Ea Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by ElsevierPITTSBURGH, Nov. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan SA has received the prestigiou Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix LaboratoriesPITTSBURGH, Nov. 10 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its privately held Indian subsidiary, Matrix La Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32-- On a GAAP basis, earnings per diluted share of $0.29 for the nine months ended September 30, 2009.Mylan's Chai Mylan Resolves Longstanding Dispute with DOJ Regarding Certain Medicaid Rebate Classifications from 2000 Through 2004PITTSBURGH, Oct. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that two of its subsidiaries have re Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Sinemet(R)PITTSBURGH, Sept. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has WHO Withdraws Notice of Concern for Mylan's Matrix UnitPITTSBURGH, Aug. 28 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today is pleased to announce that its subsidiary Matrix Laboratories Ltd Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009-- On a GAAP basis, the company reported diluted EPS of $0.19 and $0.42 for the three and six months ended June 30, 2009, compared to a lhttp://www.bioportfolio.com/news/Mylan_Reports_Adjusted_Diluted_EPS_of_%240.32_for.html - Thursday July 30 2009 Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)PITTSBURGH, July 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received a Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live WebcastPITTSBURGH, July 6 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thurs Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics MarketPITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has executed a definitive agreement with Biocon Limi Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)Product shipment has begun PITTSBURGH, June 17 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity PeriodSees opportunity to end abusive use of authorized generics during period of exclusivity PITTSBURGH, June 3 /PRNewswire-Firs Mylan's Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic DrugsPITTSBURGH, June 1 /PRNewswire-FirstCall/ -- WHAT: Mylan Inc. (Nasdaq: MYL) has accepted an invitation to testify before t Mylan Announces Successful Matrix Delisting OfferPITTSBURGH, June 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its wholly-owned subsidiary, MP Laboratories (Mauritius) Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has received tentative approval from the U.S. Food an Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive DisorderPITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that it has begun to market and di Mylan Names Jolene Varney Chief Financial OfficerPITTSBURGH, May 28 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Jolene Varney as Executive Vice President Mylan Announces Change in Board Leadership- Co-founder Mike Puskar retires as Chairman of the Board - - Robert J. Coury elected Chairman of the Board - http://www.bioportfolio.com/news/Mylan_Announces_Change_in_Board.html - Thursday May 7 2009 Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)PITTSBURGH, May 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final Mylan Reports Adjusted Diluted EPS of $0.33 for the Quarter Ended March 31, 2009Three months endedhttp://www.bioportfolio.com/news/Mylan_Reports_Adjusted_Diluted_EPS_of_%240.33_for.html - Thursday April 30 2009 Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live WebcastPITTSBURGH, April 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thu Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS TreatmentsPITTSBURGH, April 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiar Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer TreatmentExpects to qualify for 180 days of sole marketing exclusivity PITTSBURGH, April 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development PITTSBURGH, April 13 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL)
today announced the appointment of former Merrill Lynch investment bank Mylan Announces Clarinex(R) Settlement AgreementPITTSBURGH, April 8 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced the settlement of all patent litigation relating to Deslorat Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)PITTSBURGH, March 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiar Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock ExchangesPITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced its plans to purchase the remaining interest in Matrix Labo Mylan Confirms Four First-to-File ChallengesPITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it and/or a subsidiary have been sued in connection wi Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease InhibitorProvides first affordable protease inhibitor for patients in developing countries Complements recent WHO approval earned for the same producthttp://www.bioportfolio.com/news/Mylan%26apos%3Bs_Matrix_Receives_Tentative_FDA.html - Thursday March 12 2009 Provides first affordable protease inhibitor for patients in developing countries PITTSBURGH, Feb. 25 /PRNewswire-FirstCal PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Chief Financial Officer, Edward J. Borkowski, will PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Vice Chairman and CEO Robert J. Coury will preside PITTSBURGH, Feb. 16 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, Febr Company will have 180 days of marketing exclusivity on the 500 mg strength PITTSBURGH, Jan. 30 /PRNewswire/ -- Mylan Inc. ( PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm PITTSBURGH, Jan. 23 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received fina PITTSBURGH, Jan. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL)
today announced that its subsidiary Dey L.P. has been issued several
add Pittsburgh, Jan. 6 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it will present at the 27th An PITTSBURGH, Dec. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary PITTSBURGH, Nov. 17 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today
announced that its subsidiary, Mylan Pharmaceuticals Inc., received PITTSBURGH, Nov. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today
announced that its subsidiary Mylan Pharmaceuticals Inc. received fin PITTSBURGH, Oct. 22 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today
announced that its subsidiary, Mylan Pharmaceuticals Inc., received PITTSBURGH, Oct. 22 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today
confirmed that the company and its subsidiary, Mylan Pharmaceuticals |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
